edawar's characterization of rejection I as a hostversus-graft (HVG) reaction ( Fig. 1 a) donor and recipient immune-cell populations coexisted in neonatally tolerant animals in a mutually nonreactive state while retaining the ability to function colla boratively (e.g. in a joint immune response to infection) was abandoned when no direct experimental support could be found lO . However, it has since been learned that the outcome in the neonatal tolerance model is highly variable and that a state approaching permanent clonal deletion is uncommon". Recently, it has been shown that the ability nerstone of transplantation immunology. A decade later, this concept was transposed in the context of a graft-versus-host (GVH) reaction (Fig. 1b) , in which histoincompatible hematolymphopoietic grafts rejected the immunologically defenseless recipients 2 • 3
The resulting assumption that allograft acceptance or rejection could be understood by studying HVG or GVH immunologic responses in isolation led of donor-derived leukocyte subsets to proliferate in response to a to prompt acceptance of the one-way in vitro tests of immune reac-skin graft challenge was a more critical determinant of neonatal to 1-tivity as ' minitransplant' surrogates. However, this assumption did erance outcome than the baseline level of chimerism 12 , not provide a blanket explanation for observations made in animal and human allograft recipients,
The one-way paradigm
Until 1959, preparatory donor leukocyte infusion into cytoablated organ recipients was an expected natural extension of the neonatal tolerance model of Billingham, Brent and Medawarl and its adult cytoablation analogues 5 , However, when long-term survival of human kidney allografts was accomplished in a few sublethally irradiated recipients without donor leukocyte infusion, and then regularly without cytoreduction under continuous pharmacologic immunosuppression, the need either for chimerism or host preconditioning lost favor, The identification of 'passenger leukocytes' as the primary antigenic component of organs 6 . 7 led to the belief that their destruction by the host immune system was essential for organ engrafhnent. When these cells were found to be migratory, including dendritic cells (DCs)9, their sensitization effects and presumed elimination at peripheral and intragraft sites was taken for granted.
Bone marrow transplantation
Major histocompatibility complex (MHCl-restricted models of acquired tolerance were widely considered to have validated Burnet's prediction that developing lymphocytes could be purged of selfreactive cells before they achieved functional maturity, even following bone marrow transplantation, The alternative pOSSibility that
Orgon transplantation
The conclusion that organ transplant acceptance was by different unidirectional mechanisms than those of bone marrow grafts was reinforced by the striking differences between the two varieties of procedures (Table 1 ). In addition, it was generally assumed that cytoablation (or cytoreduction) to 'make microenvironmental space' was a necessary condition for leukocyte engraftment and chimerism, in spite of early and recent evidence to the contrary (reviewed in Ref. 13 . r;:~ \ *~
Defenseless recipient Billingham, Brent and Medawar
Cytoablation (X-ray, drugs) Parent -> offspring F1 hybrid after bone marrow transplantation 11 ( Fig. 1d ) , proved by demonIn a reassessment based on the discovery of microchimerism in strating a trace residual population of host leukocytes in essentially organ recipients, we suggested that the donor leukocytes in organ all stable, human bone marrow recipients who previously were recipients were co mponents of antagonistic but reciprocally ilttenuthought to have complete donor-cell chimerism"-a ted or abrogated HVG and GVH armsI4.,S.1,. Deletion of the host
Cause or effect?
In the one-way paradigm, which excludes a role for lymphoid cell microchimerism, it has become axiomiltic that antigens of the parenchymal (or vascular endothelial) cells of trilnsplanted organs permit or induce allograft acceptilncel.1 in various ways, e.g. via veto /suppressor cells, cytokine profile changes or enhancing antibodies. Furthermore, it has been argued that the microchimerism associated with successful transplantation, and conversely its disappearance with or just after irreversible rejection in experimental models 1B .20, is epiphenomenal"-
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arm by cytoablation prior to bone marrow but not organ transplantation altered the balance in this mutual antagonism and was thus respo nsible for the disparities in the two different kinds of transplantation (Table 1) . The microchimerism had consequences that could not be explained by the simple presence of antigen, as long as the balance was not disturbed and both cell populations were equally immunosuppressed. The dynamic 'nullification' effect of the two arms explained (1) the poor prognostic value of HLA matching for organ transplantation; (2) the rarity of GVH disease (GVHD) following the engra ftment of immunologically active organs, such as the intestine and liver14·,5.1" and (3) the characteristic cycle of irrununologic crisis and resolution, first observed in kidney recipients 25 , that was most-practically monitored by serial changes in organ allograft function (Fig. 2) . Finally, the discovery of chimerism cast new light on the B-cell lymphomas [post-transplant lymphoproliferative disorders (PTLDs»), that are usually of host origin in organ recipients and of donor origin after bone marrow transplantation. Except for their frequent Epstein-Barr virus association, these human malignancies are indistinguishable from those induced by Schwartz in a mouse chimerism model 26 three years before the PTI..D complication was first recognized clinically27 and explained by simple loss of surveillance 28 . By contrast, Schwartz ascribed the tumors to a ly,mphoproliferative response by the dominant immune apparatus to the persistent subclinical GVH counter-attack of the minority leukocyte population. The relevance of this conclUSion, of 'Schwartz's rules' of pathogenesis, and of their therapeutic implications could DEBATE IMMUNOLOGY TODAY not be appreciated until three decades later in the context of the two-way paradigm 29 .
The role of immunosuppression
As in Schwartz's 'lymphoma-genic' experiments, immunosuppression is a temporary requirement for reliable induction of tolerance in numerous rodent organ allograft models. The same is true, but unpredictably, after liver30 and, less commonly, kidney transplantation in outbred canines. Moreover, successful liver transplantation induces tolerance with no treatment at all in a significant percentage of outbred pigs as well as several rat lO ,31 and virtually all mouse strain combinations ' "' Mouse heart and kidney allografts are also accepted spontaneously in a much more limited number of MHC disparate conditions (reviewed in Ref. 19) . When a thorough search is made for microchimerism in the rodent models, it can always be found 19.20.32, In all these species, the organs pass through an acute selfresolving rejection on the way to tolerance, which usually extends to subsequent transplantation of other donor-strain tissues and organs 33 The tolerance is stable despite evidence from in vitro testing that anti-donor reactivity is retained (split tolerance)'9.20,31,34 or can be restored by the addition of appropriate cytokines.
The cumulative weight of the above observations does not support the possibility that microchimerism is a passive consequence of organ transplantation. Instead, an active role of the organassociated chimerism can be identified in a continuum of classical tolerance models beginning with the original observations by Owen in Freemartin cattle (Fig. 3) .
Th e stem cell question
The human chimerism studies suggested that hematopoietic stem and precursor cells were among the migratory cells from transplanted organs. In support of this contention, all lineages in supralethally irradiated mice can be reconstituted efficientl y by the infusion of non-parenchymal cells with stem cell phenotype, isolated from syngeneic adult mouse livers 3s In addition, irradiated rats can be reliably reconstituted with orthotopic liver transplantation ra ther than bone marrow 36 Importantly, heterotopic heart transplantation also results in permanent hematopoietic reconstitution in occasional irradiated rats 36 , a rescue that is increased to ;;.70% by the post-cardiac transplant administration of lisofylline (N. Murase et aI., unpublished). Lisofylline is a phosphatidic acid inhibitor that facilitates bone marrow engraftment by suppressing hematopoiesis-inhibiting cytokines (e.g. tumor necrosis factor ex, transforming growth factor 13, macrophage inhibitory protein lex and platelet factor 4) that are typically released in response to activation stimuli in the post-transplant period, while not altering levels or activities of the myeloid, progenitor-cell-promoting cytokines, granulocyte-macrophage colony-stimulating factor (GM-CSF) and G-CSF (Ref. 37) .
Such experiments show that the chimerism produced with bone marrow infusion vs. conventional organ transplantation is Vol. 17 No.12 $79
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the same, with apparent differences that are largely determined by the radically divergent treatment regimens. Consistent with this, the chimerism following transplantation of the bone-marrow-containing hind limb to non-cytoablated recipients is much the same as after engraftment of parenchymal organs 3S .
Freemartin cattle (1945)
.~
-----=.
•
Billingham , Brent and S lavin and Strober (1977)
Iidstad and Sachs (1984) Thomas (1987) However, in practical terms the outcome (HYG, GYHD or both) is strongly influenced by the lineage profile of the mature immunocytes contained either in different vital organs (hea rt, kidney, liver and intestine) or in cell suspensions prepared from various primary or secondary lymphoid organs. Non-parenchymal cells of the liver (the most tolerogenic who le organ) resemble those of bone marrow (the lymphoid organ yielding the most tolerogenic cell suspension). Both includ e higher numbers of immature leukocytes and cells of myeloid origin than the lymphocyte-rich and GYHD-prone intestinal allograft and lymph node or spleen cell suspensions 2o 
Chimerism : level and duration
The implication of human and animal studies is that the threshold level of circulating donor leukocytes necessary for a tolerogenic effect has been set too high. Although treatment strategies that directly18.19 or indirectly augment chimerism 37 • 39 in non-cytoablated experimental animals increase the reliability and comple teness of tolerance, it is not at all clear that the process can be fundamentally hastened . One postulate is that the chimeric immune cells remain susceptible to further signals that reinforce specific nonreactivity in stages 40 Rather than accelerating these steps, we have suggested that immunosuppressive agents, with diverse sites of action, merely permit them to develop (with variable success) by allowing the same underlying function of the immune system to be exp ressed as in models of spontaneous tolerance 41 (see earlier).
With liver transplantation in spontaneously tolerant and 'immunosuppression-assis ted' rodent models, the cause (chimerism) and effect (tolerance) are induced almost simultaneously but these related events are usually separated by months or yea rs in outbred animals and humans (Fig. 4) . Many long-surviving human liver recipients have become immunosuppression-independent (most frequently because of treatment noncompliance) at highly variable postoperative times (Fig. 5 ). More-complete information was obtained in a prospective weaning trial of liver recipients who had at least five years of stable allograft function 42 The majority of these The desired drug-free state might never be reached in a proportion of human liver recipients, but the disseminated donor-derived leukocytes (and their companion organ) apparently can be maintained for a lifetime under immunosuppression . Th e same principle has been demonstrated in rat cardiac and renal recipien ts in which continued immunosuppression prevented the slow disappearance of chimerism and the onset of indolent chronic rejection 2o
As in animals, discontinuance of drug therapy in humans is patients were able to stop immunosuppression or are still in an unthought to be more dangerous after transplantation of organs other interrupted weaning process· 3 : 30% developed rejection, necessitat-than the liver. However, five of the ten longest-surviving patients ing resumption of immunosuppression. No grafts were lost or had bearing Ji ving-related kidney allografts have been completely off permanent impairment of function.
immunosuppression for between three and 30 years ( Patients 3 and 4, whose mixed lymphocyte response (MLR) tests to donor and third party targets were profoundly depressed prior to weaning", had gradual restoration of MLR to both in the drug-free state, but with no evidence of rejection.
There is no empirical method to determine the necessary duration of continued immunosuppression for maintenance of stable chimerism and allograft function in humans. Thus, quantitation of donor-derived leukocytes cannot be used to plan drug weaning protocols for patients. This must be done by cautious trial, with precautions to prevent irreversible error. Such dues are intriguing, but it is unlikely that allograft acceptance can be fully understood from the results of studies of individual leukocyte lineages. Overall, the mechanisms of transplantation tolerance suggests learning adaptive immune functions of the whole system involved in selfintegrity (i.e. cytokines, immunoregulatory cells, antibodies and other factors) .
Genetic (actors
These ~re 3 of the 161ongest-tunctioning allografts in the world. "comp, complic.,tions: skin cancer, warts, iniection , hypertension, obesity and orthopedic problems. nc, non-compliant. ' These were children <1t the time oi transpl.lntation.
Transplant tolerance: central or peripheral
The role of the thymic vs. peripheral mechanisms in graft acceptance under both experimental and clinical circumstances has been controversial60-68. The prompt appearance of donor-derived leukocytes in the recipient thymus following organ transplantation'6 was of particular interest because of the strikingly tolerogenic effect in rodents of intrathymic inoculation of donor leukocytes 53 However, thymectomy in adult rats does not inAuence either the chimerism or spontaneous tolerance induced by liver transplantation 69 Dejbakhsh-Jones e/ 17/.'0 have shown that, after thymectomy and lethal irradiation, adult mice reconstituted with purified hematolymphopoietic stem cells developed similar levels of a~ T cells to those seen in control animals except for a reduced proportion in the spleen.
Between 1962 and 1965, 32 patients, including 24 who were part of a controlled randomized trial, underwent transthoracic thymectomy from 8 to 112 days (average 22) before renal transplantation either from living related or unrelated donors. Between 3.5 and 7 years later, no clinical differences were apparent between the thymectomized and control recipients, although there was a trend towards better histopathology in the thymectomized group71 . In 
Therapeutic implications
In the context of the two-way paradigm, early efforts to improve transplantation results with donor-specific blood transfusion n and the donor bone marrow augmentation of organ recipients?3.,. were based on sound therapeutic principles involving the unrecognized augmentation of chimerism. Also in retrospect, it is obvious why whole organs are inherently tolerogenic as first convincingly demonstrated by Caine e/ a/ . 32 
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Understanding the concept of a donor-recipient leukocyte dialogue should help predetermine what can (and cannot) be accomplished with various tOlerance-inducing strategies, all of which are attempts to inAuence this interaction. Our first clinical premise was that the spontaneous microchimerism of organ transplantation could be greatly augmented by the co-administration of unmodified donor bone marrow cells without a significant risk of GVHD, providing the two immunocyte populations were initially competent and that immunosuppression was delivered to both equally. It was also predicted that the timing, severity and frequency of acute rejection would be approximately the same as in non-bone-marrowaugmented control patients"·"·75. These expectation' s have been fulfilled in 150 human organ recipients treated at the Un iversity of Pittsburgh 75 .7 6 The presence of donor DNA in the myeloid and erythroid colonies generated from recipient'S peripheral blood mononuclear cells (PBMCs) as measured in standard?6 or innovative clonal hematopoietic progenitor cell assays77 has provided unequivocal evidence of augmented stem cell chimerism. There were no examples of significant GVHD.
The hypotheses of therapeutic efficacy being tested were that the threat of delayed (acute or chronic) rejection could be reduced and that the frequency of ultimate drug independence would be increased by the higher persistent level of chimerism. An efficacy evaluation is expected to take 5-10 years·', roughly the same time frame mapped out by clinical experience with MHC-incompatible liver and bone marrow transplantation (Figs 4 and 5) .
Other chimerism-enhancing strategies (e.g. G-CSF, GM-CSF or lisofylline) should follow the same safety l efficacy rules. By contrast, procedures that alter only one of the interacting arms must be approached with caution, as exemplified by the historical experience with GVHD following cytoablation and bone marrow transplantation. When the converse tactic of leukocyte or T-cell-specific depletion of intestinal allografts was attempted as GVHDprophylaxis in the 1980s, virtually every bowel recipient who survived the perioperative period developed lethal Epstein-Barr-virusassociated B-celllymphomas 711 •
In an experimental example of unbalance which has potential clinical relevance, prior induction of tolerance with bone marrow in briefly immunosuppressed rats followed by delayed liver transplantation resulted in GVHD (Ref. 19 ), a complication not seen after either bone marrow or liver transplantation, or both simultaneously. The results of the second stage transplantation resembled those in the parent to defenseless offspring F, models.
Conclusion
The assumption that stem cell driven hematolymphopoietic chimerism was irrelevant to successful whole organ transplantation, as currently practiced, has led to inadequate explanations of organ allograft acceptance and clouded the meaning of successful bone marrow transplantation, thus precluding the development of a central priI1cipie of transplantation. Incorporation of the chimerism factor into a two-way paradigm has allowed previous enigmas of organ and bone marrow engraftment to be explained and should allow key advances in basic immunology to be more meaningfully exploited in transplantation
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I!"-.... -. . . onor cells or genet ic material can often be detected in recipients followi ng trans-• _ _ . . . . . plan tation of a solid-orga n allograft. Such recipients are described as exhibiting peripheral donor microchimerism and in some cases the donor material is detected for long periods after trans plantation'-S It has been suggested not only that peripheral donor microchimerism is associated with long-term acceptance of the organ graft but that it plays an active role in the induction and maintenance of unrespo nsive- 
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Microchimerism: observations
Solid-organ grafts co ntain passenger leukocy tes 7 ,8, the number and lineage of which vary conSiderably among d ifferent organs. For example, the liver contains an abunda nt supply of passenger cells, whereas relatively few leukocytes are present within the heart 9 In additio n, the passenger leukocytes present in the li ver of rodents contain a sufficient number of haemato poietic stem cells'o to rescue a lethally irradiated recipient when a syngeneic liver graft is transness'-J·6. This hypo thesis, first proposed by Starzl and colleagues in 1992 (Ref. 1), has sti mula ted a great deal of interest and actiVity in the transplant community. However, from the published reports to da te, it remains difficul t to determ ine whether suc h microchimerism is the cause or the consequence of long-term graft survival.
planted; rescue can not be achieved reliably by the transpl antation of a sy ngeneic cardiac allograft" . Passenger leukocytes present within solid organs have been isolated and shown to possess the potential to stimulate immune responses in vitro12. However, before acquiring full immunostimulatory potential, it appears that such cells must develop into a more mature form. This has been achieved in vilro by addition of growth factors , In primary graft recipients, donor leukocytes migrating from transplanted hearts in a mouse model were only detectilble for a few days within the spleen unless the animals received immunosuppression, after Fig. 1 In contrast to donor microchimerism detectable after organ transplantation, haematolymphopoietic chimerism is achieved at readily detectable levels following administration of allogeneiC bone marrow to appropriately conditioned recipients. In this situation, bone marrow engraftment generally requires the dual strategy of ablation of the host's haematopoietic system, in order to ' make room ' for the donor marrow, along with additional immunosuppression to prevent rejection of the allogeneic cells: the former is usually achieved by irradiation or radiomimetic drugs, the latter by T-cell depletion or by immunosuppressive agents.
When bone marrow transplantation is performed to treat haematologic malignancies, complete ablation (e.g. lethal irradiation) is immunosuppression, and the chimerism established by intentional bone marrow transplantation prior to an organ transplant (Fig. 1) .
In the former case, the chronic immunosuppressive regimen must be sufficient to suppress rejection of the graft. and as such it is undoubtedly also sufficient to suppress the elimination of donor cells which might escape from the transplanted organ. Therefore, detection of such cells elsewhere in the recipient might be considered as evidence of microch imerism, but it does not impl y that the cells detected are the ca use of the graft's acceptance. On the contrary, they may be the result of the graft's acceptance and of the immunosuppression required to maintain that acceptance. is rejected if the animal is allowed to remain without a graftl 2 . 33 By contrast, when tolerance is induced by establishment of mixed chimerism, that tolerance is stable after graft remo val. A second allograft from the same donor strain will be accepted without immunogenerally used, since 100% chimerism is desired to ensure elimi-. suppression at any time thereafter, for the life of the recipient25 nation of leukaemia cells. By contrast, when chimerism is being used to induce transplantation tolerance, complete chimerism is neither necessary nor desirable. Instead, it is preferable to achieve a low but perSistent level of donor lymphohaematopoietic chimerism, so that host-type immune-cell populations are available to provide immunocompetence peripherally, while donor-derived cells (probably dendritic cells) provide a persistent source of antigen in the thymus, capable of effecting negative selection 2 '. A non-myeloablative preparati ve regimen, using sublethal irradiation and anti-T-cell monoclonal antibodies, has been demonstrated to achieve longlasting mix.ed lymphohaematopoietic chimerism without the requirement for immunosuppressive therapy beyond the immediate post-transplant period 25 . 2 .. Data from these studies showed that T-cell depletion and partial ablation of the recipient's immune system before bone marrow infusion were required to achieve the persistent level of chimerism necessary to induce tolerance. This is not to say that detection of chimerism is not important in both cases. Indeed, regardless of the mechanism responsible for the establishment of mixed chimerism, its detection might serve as a marker for graft acceptance, and thus might be useful diagnostically. Indeed, cells from the donor which escape to other sites might playa role in diminishing the immune response to the transplant 22 However, since detectable microchimerism after organ transplantation is not a consistent finding in patients with short-or long-term stable graft function'';, and microchimerism has been shown to persist in patients during graft rejection 23 , it might only be useful as a marker in conjunction with other parameters 3 The detection or lack of detection of donor microchimerism after solid-organ transplantation alone may be misleading.
Clinical implications
Starzl and colleagues ha ve proposed a paradigm in which the states of immunologic tolerance achieved either by bone marrow transDifferences between the forms of chimerism detected plantation or by organ transplantation are linked by a common dein these situations pendence on the presence of haematopoietic chimerism"" The deThere is a fundamental difference between the microchimerism de-scription of this paradigm is important both because it provides a tected following allogeneic organ transplantation using standard theoretical construct for understanding the complex interactions between host and graft that occur following any transplant, and because it suggests experimental manipulations which increase the likeli hood of tolerance ind uctio n and which are therefore worthy of further tes ting. However, g iven the likely differences in mechan ism by which chi merism is achieved in these two d istinct situations, it would be prema ture and potentially dangerous to d iscon tinue immu nosupp ression in transplant patients solely on the basis 01 the detection of peripheral microchimeris m. Im mu nosu ppression generally dim inishes T-cell responses by suppressing the activity of T cells capable of recognizing the transplanted tissue rather than by eliminating th em. Therefore, when immunosuppression is stopped, T-cell reactivity to the transplant can be expected to return, unless some additional mechanism to delete o r inhibit the acti vity of donor-reactive T ce lls is acquired in the interim. Such mechanisms may exist and sho uld be explored. For example, it might be possible to induce specific anergy among residual T cells during the period 01 immunosuppression)4. Alterna tively, if cells from the transpla nt migrate to sites capable of achieving negative selection 01 new T cells, e.g. the thymus, and if sufficien t time passes during the period of immu nosuppression lor existing T cells to be replaced , then a deJetional tolera nce could result. However, some T cells are known to be extremely long-li ved)', thus the period necessary for s uch a resu lt to be achieved could be long and variable. Clearly, additional laboratory studies directed towards elu cidating the mechanisms by which the unresponsive sta te is maintained are essential before it will be safe to discon tinue immunosuppression in clinical transplantation.
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